staurosporine has been researched along with vorinostat in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bolognini, D; Cattaneo, E; Kazantsev, AG; Mutti, C; Rigamonti, D; Sola, F; Tartari, M; Valenza, M; Zuccato, C | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aly, AH; Debbab, A; Diederich, M; El Amrani, M; Feger, D; Gaigneaux, A; Lai, D; Lin, W; Proksch, P; Schnekenburger, M; Seidel, C; Siems, K | 1 |
| Chen, SS; Lee, HY; Lee, S; Liu, YT; Tai, HC; Tuan, YL; Wang, HH; Wang, SW; Yen, JY; Yu, CL | 1 |
| Choy, ML; Lee, JH; Marks, PA; Ngo, L; Venta-Perez, G | 1 |
| Lancet, JE | 1 |
1 review(s) available for staurosporine and vorinostat
| Article | Year |
|---|---|
New agents: great expectations not realized.
Topics: Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Benzothiazoles; Cytosine; Gemtuzumab; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Naphthyridines; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Staurosporine; Survival Analysis; Thiazoles; Treatment Failure; Vorinostat | 2013 |
5 other study(ies) available for staurosporine and vorinostat
| Article | Year |
|---|---|
Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Survival; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Gene Silencing; Huntingtin Protein; Immunohistochemistry; Luciferases; Models, Chemical; Nerve Tissue Proteins; Neurons; Nuclear Proteins; Peptides; Rats; Transcription Factors | 2007 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.
Topics: Ascomycota; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Mentha; Molecular Structure; Morocco; Nuclear Magnetic Resonance, Biomolecular; Plant Leaves; Polyketides; Protein Kinase Inhibitors; Protein Kinases; Structure-Activity Relationship | 2014 |
Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2.
Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Molecular Structure; Phenylurea Compounds; Protein Kinase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2021 |
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors.
Topics: Animals; Cell Line, Tumor; Cell Survival; Cells, Cultured; Checkpoint Kinase 1; DNA Damage; Drug Resistance; Fibroblasts; Foreskin; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunoblotting; Male; Mice; Protein Kinases; Quinolines; Quinuclidines; RNA Interference; Spleen; Staurosporine; Thiophenes; Urea; Vorinostat | 2011 |